Australian pharmaceutical company CSL revealed a major restructuring plan involving spinning off its influenza vaccine business, Seqirus, into a standalone company and cutting up to 15% of its global workforce. The changes aim to reduce fixed costs, boost pipeline productivity, and improve R&D efficiency while saving between $500 million to $550 million annually over three years. The Seqirus de-merger is expected to complete by June 2026, enabling independent strategic focus. Despite a modest 2% revenue increase in vaccines, CEO Paul McKenzie described the U.S. market softness as a competitive challenge amid a dynamic geopolitical landscape and scrutiny on vaccine products.